Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | ALPL | P05186 | 1/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | TTK | P33981 | 1/20 | 0.71 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.71 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.68 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.68 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.66 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.66 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.66 |
| ▸ | MAP2K4 | P45985 | 5/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.60 |
| ▸ | MAPK6 | Q16659 | 4/20 | 0.60 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.60 |
| ▸ | MAPKAPK3 | Q16644 | 3/20 | 0.60 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17178615 | 0.84 | ALDH1A1 (0.92) | IDO1KDM4EALDH1A1ALPLGAA | |
| SCHEMBL855531 | 0.84 | ALDH1A1 (1.00) | IDO1KDM4EALDH1A1ALPLGAA | |
| SCHEMBL30768403 | 0.84 | ALDH1A1 (1.00) | IDO1KDM4EALDH1A1ALPLGAA | |
| SCHEMBL1672674 | 0.81 | IDO1 (0.78) | IDO1KDM4EALDH1A1ALPLGAA | |
| SCHEMBL5377572 | 0.81 | ALDH1A1 (0.71) | IDO1KDM4EALDH1A1ALPLGAA | |
| SCHEMBL12318475 | 0.81 | KDM4E (0.71) | IDO1KDM4EALDH1A1ALPLGAA | |
| SCHEMBL28982378 | 0.81 | IDO1 (0.71) | IDO1KDM4EALDH1A1ALPLGAA | |
| SCHEMBL4480025 | 0.81 | ALDH1A1 (0.71) | IDO1KDM4EALDH1A1ALPLGAA | |
| SCHEMBL5381079 | 0.81 | IDO1 (0.71) | IDO1KDM4EALDH1A1ALPLGAA | |
| SCHEMBL4035759 | 0.80 | IDO1 (0.61) | IDO1KDM4EALDH1A1ALPLGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101142235-A | Estrogen receptor structures | WYETH CORP (US) | 2008-03-12 | — | — | CN | claimed |
| EP-1856151-A2 | ESTROGEN RECEPTOR STRUCTURE | Wyeth (US) | 2007-11-21 | — | — | EP | claimed |
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | WYETH (US) | 2007-09-27 | — | — | US | claimed |
| CN-1321984-C | Substituted 4- (indazol-3-yl) phenols as Estrogen Receptor (ER) ligands and their use in the treatment of inflammation | WYETH CORP (US) | 2007-06-20 | — | — | CN | claimed |
| WO-2006078733-A2 | ESTROGEN RECEPTOR STRUCTURE | WYETH (US) | 2006-07-27 | — | — | WO | claimed |
| US-20060111421-A1 | Method of treating or preventing myocardial ischemia-reperfusion injury using NF-kB inhibitors | WYETH (US) | 2006-05-25 | — | — | US | claimed |
| CN-1692102-A | Substituted 4- (indazol-3-yl) phenols as Estrogen Receptor (ER) ligands and their use in the treatment of inflammation | WYETH CORP (US) | 2005-11-02 | — | — | CN | claimed |
| EP-1542976-A1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | Wyeth (US) | 2005-06-22 | — | — | EP | claimed |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2004-08-26 | — | — | US | claimed |
| WO-2004031159-A1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH (US) | 2004-04-15 | — | — | WO | claimed |
| US-7601847-B2 | Via lithium bis(trimethylsilyl)amide, lithium dicyclohexylamide, or potassium bis(trimethylsilyl)amide base and alkylating agent; atherosclerosis, myocardial infarction, congestive heart failure, inflammatory bowel disease, arthritis, type II diabetes, multiple sclerosis and rheumatoid arthritis | WYETH (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601847-B2 | Via lithium bis(trimethylsilyl)amide, lithium dicyclohexylamide, or potassium bis(trimethylsilyl)amide base and alkylating agent; atherosclerosis, myocardial infarction, congestive heart failure, inflammatory bowel disease, arthritis, type II diabetes, multiple sclerosis and rheumatoid arthritis | WYETH (US) | 2009-10-13 | — | — | US | disclosed |
| EP-1542976-B1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH CORP (US) | 2009-02-04 | — | — | EP | disclosed |
| US-7304073-B2 | Method of treating myocardial ischemia-reperfusion injury using NF-kB inhibitors | WYETH (US) | 2007-12-04 | — | — | US | disclosed |
| CN-101054364-A | Substituted 4-(indazol-3-yl)phenols as estrogen receptor (ER) ligands and their use in the treatmentof inflammarory diseases | WYETH CORP (US) | 2007-10-17 | — | — | CN | disclosed |
| EP-1313711-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002010137-A9 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARM INC (US) | 2003-02-06 | — | — | WO | disclosed |
| WO-2002010137-A9 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARM INC (US) | 2003-02-06 | — | — | WO | disclosed |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2002-08-01 | — | — | US | disclosed |
| WO-2002010137-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | INSR, TNNI3, INSRR | IDO1 98/4885KDM4E 339/4885ALDH1A1 2279/4885 |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | INSR, MSR1, TNNI3 | IDO1 56/4885KDM4E 408/4885ALDH1A1 1965/4885 |
| US-20060111421-A1 | Method of treating or preventing myocardial ischemia-reperfusion injury using NF-kB inhibitors | IKBKB, NFKBIA, IKBKG | IDO1 3347/4885KDM4E 2247/4885ALDH1A1 1366/4885 |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | IDO1 1010/4885KDM4E 3665/4885ALDH1A1 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.